This webinar provides an up-to-date overview of key developments in immunotoxicology, with a focus on their implications for drug development. It examines the range of immune-related adverse effects, from inflammation to autoimmunity, and outlines the nonclinical assays and testing strategies used to identify and characterise these risks. The session also reviews current regulatory guidance relevant to immunotoxicity assessment, supporting a more consistent and science-based approach to safety evaluation.

Target audience
This session is intended for toxicologists, nonclinical safety scientists, and professionals involved in drug development and regulatory assessment. It is particularly relevant for those working in pharmaceutical R&D, contract research organisations, and regulatory agencies who need to evaluate or interpret immunotoxicity data in a preclinical context.